THERAPEUTICAL SURGICAL CHOICES FOR BILATERAL BREAST CANCER- CASE PRESENTATION

2003 ◽  
Vol 13 (Suppl 1) ◽  
pp. 88.1-88
Author(s):  
P. C. Bratila ◽  
O. Nicodin ◽  
N. Niculescu ◽  
M. Serban ◽  
E. Raducea Barbulea ◽  
...  
2015 ◽  
Vol 6 (8) ◽  
pp. 367-372
Author(s):  
Bogdan Deleanu ◽  
Radu Prejbeanu ◽  
Dan Crisan ◽  
Dinu Vermesan ◽  
Vlad Predescu ◽  
...  

2019 ◽  
Vol 15 (1) ◽  
pp. 59-62 ◽  
Author(s):  
Sertac Ata Guler ◽  
◽  
Turgay Simsek ◽  
Gokhan Posteki ◽  
Alican Guresin ◽  
...  

2020 ◽  
pp. 1-2
Author(s):  
N. Murugesan ◽  
M. Amudhan ◽  
M.S. Viswanathan ◽  
Bhanumati Bhanumati ◽  
Muthuraj Muthuraj ◽  
...  

This is a presentation of four rare and interesting cases of bilateral breast cancer. The cases vary from Synchronous double primary carcinoma breast, bilateral infiltrating ductal carcinoma, bilateral synchronous metastatic carcinoma and metachronous breast carcinoma. The incidence of developing either primary or metastatic carcinoma in the other breast is increased in patients who already have carcinoma in one side and mammography contributes greatly to the detection of these lesions. (1) It is of significant prognostic value and important in deciding the clinical management based on the classification whether it is a primary or a secondary lesion.


Author(s):  
Inês Morais Rodrigues ◽  
Fernando Igreja ◽  
Isabel Riscado ◽  
Rosa Madureira ◽  
Ana Nobre Pinto

2021 ◽  
Vol 1 (31) ◽  
pp. 20-24
Author(s):  
M. V. Kalugin ◽  
K. A. Ivanova ◽  
E. I. Borisova ◽  
S. S. Nakhapetyan ◽  
S. L. Gutorov

In most cases triple negative breast cancer is characterized by an aggressive course of disease and early development of resistance to chemotherapy. Thereafter, the late-line treatment choice, usually after anthracyclines and taxanes, is problematic due to the limited amount of effective and low-toxic cytostatics. In our opinion, in this situation the use of eribulin which possesses unique antitumor action mechanisms is a good option. An illustrative case of a pronounced antitumor effect of eribulin in metastatic breast cancer with triple negative phenotype resistant to previous lines of chemotherapy is presented.


2014 ◽  
Vol 19 ◽  
Author(s):  
Doulira Louati ◽  
Khaled Trigui ◽  
Donia Abid ◽  
Salma Kammoun ◽  
Manel Dermech ◽  
...  

2013 ◽  
Vol 37 (4) ◽  
pp. 746-749 ◽  
Author(s):  
Elisa Francone ◽  
Marco J. Nathan ◽  
Federica Murelli ◽  
Maria Santina Bruno ◽  
Enrico Traverso ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document